

Angelo Di Leo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4151103/publications.pdf>

Version: 2024-02-01

183
papers

15,533
citations

30551

56
h-index

20625

120
g-index

186
all docs

186
docs citations

186
times ranked

19721
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
2	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25
3	Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. <i>Npj Breast Cancer</i> , 2021, 7, 11.	2.3	16
4	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	1.7	17
5	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2640.	1.7	8
6	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , 2021, 13, 2762.	1.7	14
7	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
8	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
9	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52
10	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
11	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReND Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139.	3.2	40
12	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	1.1	19
13	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 666.	1.3	113
14	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. <i>Breast Journal</i> , 2019, 25, 1225-1229.	0.4	0
15	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. <i>Npj Breast Cancer</i> , 2019, 5, 26.	2.3	12
16	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , 2019, 74, 29-34.	3.4	23
17	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 5.	2.3	352
18	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 392-398.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReND trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
20	A meta-analysis of clinical benefit rates for fulvestrant 500Åmg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. <i>Breast Cancer</i> , 2019, 26, 703-711.	1.3	5
21	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptorâ€“positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , 2019, 114, 55-66.	1.3	30
22	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptorâ€“Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72
23	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	0.8	16
24	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
25	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€“298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
26	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	0.9	35
27	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 371-382.	5.1	327
28	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , 2019, 11, 1894.	1.7	53
29	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	1.4	3
30	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. <i>Breast</i> , 2019, 48, S81-S84.	0.9	1
31	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. <i>Journal of Clinical Oncology</i> , 2019, 37, 538-538.	0.8	0
32	Abstract 2471: Pan-cancer catalog of Differentially Methylated Regions by Rocker-meth, a new computational method. , 2019, , .		0
33	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TReND trial. , 2019, , .		0
34	Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , .		0
35	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9
36	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	3.0	76

#	ARTICLE	IF	CITATIONS
37	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.4	50
38	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149.	0.9	10
39	Metabolomics in breast cancer: A decade in review. <i>Cancer Treatment Reviews</i> , 2018, 67, 88-96.	3.4	87
40	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	1.1	5
41	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	1.1	17
42	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39.	5.1	717
43	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 87-100.	5.1	307
44	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
45	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. <i>BMC Genomics</i> , 2018, 19, 960.	1.2	22
46	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	5
47	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , 2018, 4, 41.	2.3	41
48	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 38.	2.3	78
49	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	1.1	6
50	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1385-1393.	5.1	342
51	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 467-468.	0.4	0
52	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 4839-4845.	0.5	5
53	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
54	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14

#	ARTICLE	IF	CITATIONS
55	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1048-1048.	0.8	2
56	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. Journal of Clinical Oncology, 2018, 36, 503-503.	0.8	15
57	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	0.8	0
58	Abstract CT040: MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis. , 2018, , .		1
59	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3. , 2018, , .		3
60	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. Clinical Cancer Research, 2017, 23, 1422-1431.	3.2	65
61	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 922-928.	1.7	26
62	Recurrence dynamics of breast cancer according to baseline body mass index. European Journal of Cancer, 2017, 87, 10-20.	1.3	35
63	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308.	0.8	53
64	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. Breast, 2017, 34, S13-S18.	0.9	6
65	RE: Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2017, 109, 1.	3.0	2
66	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3638-3646.	0.8	1,099
67	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 ⁻) metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	0.8	14
68	Abstract CT010: Efficacy results based onPIK3CAstatus in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor. , 2017, , .		0
69	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget, 2016, 7, 26107-26119.	0.8	136
70	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor ⁺ Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5755-5764.	3.2	20
71	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 936-944.	0.8	17
72	Metabolomics in Breast Cancer: Current Status and Perspectives. Advances in Experimental Medicine and Biology, 2016, 882, 217-234.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes. <i>Breast</i> , 2016, 27, 189.	0.9	0
74	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , 2016, 106, 92-100.	3.1	4
75	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	2.0	15
76	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. <i>Oncotarget</i> , 2016, 7, 68012-68022.	0.8	110
77	Serum metabolomics as biomarkers to differentiate early from metastatic disease and predict relapse in elderly colorectal cancer (CRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10042-10042.	0.8	0
78	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. <i>EPMA Journal</i> , 2015, 6, 17.	3.3	12
79	A multifactorial "Consensus Signature"™ by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2015, 1, 15003.	2.3	3
80	Predicting Anthracycline Benefit: TOP2A and CEP170 Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	0.8	55
81	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
82	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. <i>Molecular Oncology</i> , 2015, 9, 128-139.	2.1	82
83	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2015, 9, 749-757.	2.1	146
84	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2+ advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104.	3.4	22
85	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer "Advancing from Prognostic to Predictive Potential. <i>Current Breast Cancer Reports</i> , 2015, 7, 53-58.	0.5	0
86	Final 10-year results of the Breast International Group 2008 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
87	Continued value of adjuvant anthracyclines as treatment for early breast cancer. <i>Lancet Oncology</i> , 2015, 16, e362-e369.	5.1	50
88	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , 2015, 33, 1574-1583.	0.8	146
89	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , 2015, 13, 46.	2.3	27
90	Tailoring therapies "improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449

#	ARTICLE	IF	CITATIONS
91	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
92	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330.	0.9	42
93	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. <i>Breast</i> , 2015, 24, S136-S142.	0.9	17
94	Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. , 2015, , .		0
95	Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 568-568.	0.8	0
96	Abstract 371: Longitudinal genetic characterization of circulating tumor cells in metastatic breast cancer patients. , 2015, , .		0
97	Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?. <i>Cancers</i> , 2014, 6, 684-707.	1.7	28
98	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. <i>Current Opinion in Oncology</i> , 2014, 26, 568-575.	1.1	33
99	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R43.	2.2	43
100	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337.	3.0	218
101	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€98. <i>Psycho-Oncology</i> , 2014, 23, 173-182.	1.0	55
102	<i>TP53</i> mutationâ€correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in <i>TP53</i>â€mutated breast cancers. <i>Molecular Oncology</i> , 2014, 8, 508-519.	2.1	59
103	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210
104	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , 2014, 23, 473-481.	0.9	11
105	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1025-1025.	0.8	1
106	Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 640-640.	0.8	0
107	A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9546-9546.	0.8	0
108	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 630-630.	0.8	0

#	ARTICLE	IF	CITATIONS
109	ecancermedalscience. Ecancermedalscience, 2013, 7, 299.	0.6	17
110	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	3.4	106
111	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 2013, 31, 860-867.	0.8	1,342
112	The continued evidence from overviews: What is the clinical utility?. Breast, 2013, 22, S8-S11.	0.9	1
113	HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact. Cancer Treatment Reviews, 2013, 39, 947-957.	3.4	66
114	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist, 2013, 18, 1063-1073.	1.9	75
115	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 2013, 138, 149-155.	1.1	16
116	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncology, 2013, 9, 1477-1487.	1.1	11
117	The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study. PLoS ONE, 2013, 8, e62543.	1.1	32
118	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 3-8.	1.8	5
119	Polyendocrine Treatment in Estrogen Receptor-Positive Breast Cancer: A FACT-Yet to Be Proven. Journal of Clinical Oncology, 2012, 30, 1897-1900.	0.8	10
120	Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. International Journal for Quality in Health Care, 2012, 24, 411-418.	0.9	28
121	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Research, 2012, 14, R70.	2.2	52
122	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1879-1887.	0.8	388
123	Metabolomics in cancer: A bench-to-bedside intersection. Critical Reviews in Oncology/Hematology, 2012, 84, 1-7.	2.0	74
124	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. Molecular Oncology, 2012, 6, 437-444.	2.1	73
125	Targeting Metabolomics in Breast Cancer. Current Breast Cancer Reports, 2012, 4, 249-256.	0.5	5
126	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	1.1	106

#	ARTICLE	IF	CITATIONS
127	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , 2012, 118, 2603-2614.	2.0	265
128	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 283-289.	1.1	101
129	The nutritional risk in oncology: a study of 1,453 cancer outpatients. <i>Supportive Care in Cancer</i> , 2012, 20, 1919-1928.	1.0	142
130	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. <i>Breast</i> , 2012, 21, 336-342.	0.9	12
131	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1BA671-1BA671.	0.8	36
132	Predictive molecular markers of anthracycline effectiveness in early breast cancer. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 16-21.	2.2	1
133	Uncovering the metabolomic fingerprint of breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1010-1020.	1.2	77
134	Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. <i>European Journal of Cancer</i> , 2011, 47, S370-S372.	1.3	11
135	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2011, 12, 1134-1142.	5.1	165
136	Adjuvant systemic treatment for individual patients with triple negative breast cancer. <i>Breast</i> , 2011, 20, S135-S141.	0.9	14
137	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. <i>Breast</i> , 2011, 20, S45.	0.9	0
138	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. <i>Current Breast Cancer Reports</i> , 2011, 3, 24-33.	0.5	0
139	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. <i>Future Oncology</i> , 2011, 7, 173-186.	1.1	4
140	Multifactorial Approach to Predicting Resistance to Anthracyclines. <i>Journal of Clinical Oncology</i> , 2011, 29, 1578-1586.	0.8	169
141	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	0.6	15
142	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 145-153.	1.1	137
143	Re-searching anthracycline therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 171-175.	1.1	8
144	Management of triple negative breast cancer. <i>Breast</i> , 2010, 19, 312-321.	0.9	171

#	ARTICLE	IF	CITATIONS
145	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600.	0.8	553
146	Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1281-1288.	3.2	32
147	Ode to a Past Emperor. <i>Journal of Clinical Oncology</i> , 2010, 28, 2938-2940.	0.8	0
148	Breast cancer assessment tools and optimizing adjuvant therapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 725-732.	12.5	83
149	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 22-36.	12.5	97
150	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2010, 26, 767-775.	0.9	13
151	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3908-3915.	0.8	154
152	Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1735-1736.	3.0	4
153	Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5552-5558.	0.8	49
154	Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 720-725.	0.8	23
155	Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?. <i>Breast</i> , 2009, 18, S18-S24.	0.9	6
156	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 523-530.	1.1	199
157	Taxanes in the elderly: Can we gain as much and be less toxic?. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 262-271.	2.0	18
158	The role of topoisomerase II α and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. <i>Cancer Treatment Reviews</i> , 2009, 35, 662-667.	3.4	30
159	Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 205.	2.2	66
160	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. <i>Radiotherapy and Oncology</i> , 2009, 90, 116-121.	0.3	16
161	Predicting anthracycline benefit: have we made any progress?. <i>Current Opinion in Oncology</i> , 2009, 21, 507-515.	1.1	9
162	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq0 0 OrigBT /Overlock 10 TF		

#	ARTICLE	IF	CITATIONS
163	Topoisomerase II alpha as a marker predicting anthracyclinesâ€™ activity in early breast cancer patients: Ready for the primetime?. <i>European Journal of Cancer</i> , 2008, 44, 2791-2798.	1.3	35
164	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7861-7870.	3.2	159
165	Class III β -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4511-4516.	3.2	58
166	Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream. <i>Journal of Clinical Oncology</i> , 2008, 26, 5011-5013.	0.8	18
167	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5544-5552.	0.8	407
168	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 121-133.	3.0	140
169	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). <i>European Journal of Cancer</i> , 2007, 43, 725-735.	1.3	49
170	Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. <i>European Journal of Cancer</i> , 2007, 43, 2270-2278.	1.3	26
171	Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications. <i>Journal of Clinical Oncology</i> , 2007, 25, 2840-2846.	0.8	217
172	Gastric Cancer Metastatic to the Pituitary Gland: A Case Report. <i>Tumori</i> , 2007, 93, 217-219.	0.6	10
173	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 1-8.	2.0	2
174	Using specific cytotoxics with a targeted mind. <i>Breast</i> , 2007, 16, 120-126.	0.9	35
175	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2572-2579.	1.9	72
176	Chemotherapy for metastatic breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2004, 16, 37-41.	0.9	19
177	Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2045-2047.	0.8	69
178	Current Status of HER2 Testing. <i>Oncology</i> , 2002, 63, 25-32.	0.9	48
179	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. <i>Cancer Treatment Reviews</i> , 2002, 28, 275-290.	3.4	6
180	Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin. <i>Journal of Clinical Oncology</i> , 2002, 20, 1145-1146.	0.8	19

#	ARTICLE	IF	CITATIONS
181	Equivalence Between Ovarian Suppression and Chemotherapy in the Adjuvant Treatment of Endocrine-Responsive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1954-1955.	0.8	6
182	HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. <i>Clinical Cancer Research</i> , 2002, 8, 1107-16.	3.2	195
183	Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3103-3110.	0.8	157